Observational studyJAMA network open2025
Incidence and Remission of Atopic Dermatitis in a German Birth Cohort.
Observational study in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Global Prevalence of Asthma in Adults with Atopic Dermatitis and the Atopic Dermatitis-Asthma Association.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Patterns of incidence and factors associated with remission of atopic dermatitis (AD) from birth to adulthood remain understudied. Objectives: To examine incidence of AD, its remission probability and trajectories, and early-life factors associated with it in a prospective study from birth to 30 years. Design, Setting, and Participants: This cohort study used data from the population-based Multicenter Allergy Study (MAS), which recruited full-term newborns from 5 German cities in 1990. Generally healthy newborns were enrolled; the sample was slightly enriched for allergy risk, with more than a third of participants born with 2 parents or siblings with allergies. Until age 30 years, participants were assessed by parental or self-report questionnaires (20 times) and clinical evaluations, including serum samples (9 times). Exposures: Age, sex, age of AD onset, parental allergy status, early-life sensitization against common food and aero-allergens, rhinitis during ages 3 to 5 years, and asthma at age 6 years. Main Outcomes and Measures: AD was determined by standardized questionnaire and doctor's diagnoses. AD remission was defined as being symptom-free for at least 12 months. Results: Among 1314 recruited participants, 707 (57%) had 1 or 2 allergic parents. Overall, 482 (37%) participated at the 30-year follow-up. The cumulative incidence of AD during the first 5 years was 57% (402 participants) with 1 or 2 allergic parents and 43% (225 participants) with nonallergic parents. The yearly rate of new AD cases declined from age 2 until 13 years and increased slightly thereafter. Among 529 participants with AD onset in the first 5 years of life, 459 (87%) reported no symptoms at age 20 and 30 years. Using data from 658 participants, 4 remission trajectories were identified: early childhood, early school age, substantial adolescence, and partial adulthood remission. Onset within first 2 years of life (adjusted risk ratio [aRR], 1.59; 95%- CI, 1.12-2.26), female sex (aRR, 1.56; 95% CI, 1.23-2.00), early allergic sensitization against at least 1 common aero- or food allergen (aRR, 1.95; 95% CI, 1.25-3.05), asthma at age 6 years (aRR, 2.22; 95% CI, 1.70-2.89), and allergic rhinitis at ages 3 to 5 years (aRR, 1.54; 95% CI, 1.21-1.95) were associated with the persistent phenotype. Conclusions and Relevance: In this cohort study of children with allergic diseases, AD before school age was generally associated with a favorable long-term prognosis. However, remission was less likely in female participants, those with onset before age 2 years, those with specific serum antibodies to common allergens before school age, or those with allergic comorbidity, highlighting the need for increased clinical attention and further investigation into underlying mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.